Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080545 · ClinicalTrials.gov registry record · Phase 4
Enstilar in Combination With Biologic Agents
A Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT03080545: Completed Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
NCT03080545 is a Phase 4 study that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03080545, a Phase 4 study, has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
Primary Outcome
pga x bsa
Interventions
- DRUG Enstilar 0.005%-0.064% Topical Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 4 |
What the finished NCT03080545 record still lists
NCT03080545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Enstilar 0.005%-0.064% Topical Foam is the first listed.
NCT03080545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03080545 about?
NCT03080545 is a clinical study titled "Enstilar in Combination With Biologic Agents". Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
What is the current status of trial NCT03080545?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2017-05-01. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT03080545?
The interventions under investigation include: Enstilar 0.005%-0.064% Topical Foam (DRUG).
Who is sponsoring clinical trial NCT03080545?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03080545's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI